Spyre Therapeutics Inc. (SYRE), which made significant advancements in its next-generation inflammatory bowel disease pipeline in 2024, has two clinical trial data releases planned for this year.
The company's lead drug candidate is SPY001, a novel, subcutaneous extended half-life monoclonal antibody targeting a4ß7 for the potential treatment of inflammatory bowel disease. Integrin a4ß7 plays a crucial role in the pathogenesis of inflammatory bowel disease.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com